Crossmark

Drugs used in diabetes, statins and the risk of rhabdomyolysis reporting: a disproportionality analysis in the world health organization’s pharmacovigilance database

Crossref DOI link: https://doi.org/10.1007/s00592-025-02550-y

Published Online: 2025-07-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Montastruc, Jean-Louis https://orcid.org/0000-0001-6341-6001
License Information

Text and Data Mining valid from 2025-07-24

Version of Record valid from 2025-07-24
More Information

Article History

Received: 27 January 2025

Accepted: 2 June 2025

First Online: 24 July 2025

Declarations

:

: JLM has no conflict of interest.

: The author confirms that the principal investigator for this paper is Professor Jean-Louis Montastruc. No direct clinical responsibility for patients was needed since the work was performed using the global pharmacovigilance database, VigiBase ® .

: The work was performed using the database, Vigibase ® which is freely available to the author. None informed consent was required from patients since the database Vigibase ® is anonymized. Institutional review board approval was not required because Vigibase ® is an anonymized database open to pharmacovigilance centers.

Document is current

Any future updates will be listed below